EyeGene Inc (185490) - Total Liabilities

Latest as of March 2026: ₩13.78 Billion KRW ≈ $9.34 Million USD

Based on the latest financial reports, EyeGene Inc (185490) has total liabilities worth ₩13.78 Billion KRW (≈ $9.34 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

EyeGene Inc - Total Liabilities Trend (2014–2025)

This chart illustrates how EyeGene Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is EyeGene Inc's working capital to evaluate short-term liquidity relative to the company's equity base.

EyeGene Inc Competitors by Total Liabilities

The table below lists competitors of EyeGene Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Energía Innovación y Desarrollo Fotovoltaico S.A. MC:EIDF	Spain	€104.09 Million
BPL Limited NSE:BPL	India	Rs3.28 Billion
Eastern Commercial Leasing Public Company Limited BK:ECL	Thailand	฿3.14 Billion
Australian Mines Ltd AU:AUZ	Australia	AU$207.00K
FingerMotion Inc NASDAQ:FNGR	USA	$45.70 Million
ENERGIA IN.Y DES. EO 025 F:F63	Germany	€119.79 Million
Xali Gold Corp V:XGC	Canada	CA$13.83 Million
Lotus KFM Bhd KLSE:8303	Malaysia	RM23.52 Million

Liability Composition Analysis (2014–2025)

This chart breaks down EyeGene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EyeGene Inc (185490) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.37	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.21	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how EyeGene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for EyeGene Inc (2014–2025)

The table below shows the annual total liabilities of EyeGene Inc from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩13.80 Billion ≈ $9.35 Million	-7.91%
2024-12-31	₩14.98 Billion ≈ $10.15 Million	+8.83%
2023-12-31	₩13.77 Billion ≈ $9.33 Million	+0.85%
2022-12-31	₩13.65 Billion ≈ $9.25 Million	-14.79%
2021-12-31	₩16.02 Billion ≈ $10.86 Million	-49.18%
2020-12-31	₩31.53 Billion ≈ $21.37 Million	+11.49%
2019-12-31	₩28.28 Billion ≈ $19.16 Million	-7.88%
2018-12-31	₩30.70 Billion ≈ $20.80 Million	+370.07%
2017-12-31	₩6.53 Billion ≈ $4.43 Million	+175.39%
2016-12-31	₩2.37 Billion ≈ $1.61 Million	+51.49%
2015-12-31	₩1.57 Billion ≈ $1.06 Million	-7.33%
2014-12-31	₩1.69 Billion ≈ $1.14 Million	--

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$29.03 Million

₩42.83 Billion KRW

Market Cap Rank

#23926 Global

#1646 in Korea

Share Price

₩1406.00

Change (1 day)

+0.07%

52-Week Range

₩1193.00 - ₩3630.00

All Time High

₩50300.00